用透析治疗的ADPKD患者中风风险:一项回顾性研究
Damiano Cerasuolo1,2, Darbelis Tejeda-Reyes1, Cécile Couchoud3
1Biostatistics and Clinical Research Unit, Caen-Normandy University Hospital, Caen, France.
Clinical kidney journal
|April 10, 2025
概括
在透析中患有自身主导性多囊性病 (ADPKD) 的患者不会面临增加的中风风险. 这一发现表明,在透析和脱离透析的ADPKD患者中,类似的查策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 神经学 神经学
- 流行病学 流行病学
背景情况:
- 与未透析患者相比,透析期末病 (ESRD) 患者的中风风险增加了一倍.
- 自体主导多囊性病 (ADPKD) 与脑内动脉瘤有关,但其在ESRD患者中风发作中的作用尚不清楚.
研究的目的:
- 为了研究ADPKD和中风风险在接受脏替代疗法的患者之间的关联.
- 确定ADPKD是否影响透析患者中风发生率.
主要方法:
- 分析了2015-2019年间开始透析的40980名患者,使用了REIN注册和法国国家健康数据系统 (SNDS) 的数据.
- 使用ICD-10代码识别中风病例,首次观察到的中风是主要事件.
- 用一个半参数生存模型来分析数据.
主要成果:
- 在透析中,中风的总累积发病率为每100人/年1.58.
- 在2,182名ADPKD患者中,44名 (2%) 患有中风.
- 在调整了主要风险因素后,ADPKD与任何类型的中风风险增加没有显著关联.
结论:
- 在接受透析的ADPKD患者中没有观察到中风风险的增加.
- 目前的发现支持在ADPKD患者中应用相同的中风查策略,无论他们是否在透析.
相关概念视频
Dialysis
235
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
235
Renal Failure: Dose Adjustments
38
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
38
Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
Kidney Structure
67.2K
The kidneys are two large bean-shaped organs located in the upper abdomen. They filter the blood several times a day to remove toxins and rebalance water and electrolytes of the circulatory system via the renal veins. The kidneys receive blood directly from the heart via the renal arteries. These arteries enter the kidney at the hilum, the concave surface of the bean, where they branch and divide into smaller vessels and capillaries.
67.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329


